Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Allogeneic transplant leads to durable remissions in T-cell lymphomas
Key clinical point: In patients with T-cell lymphoma, allogeneic transplant can lead to durable remissions among patients who might otherwise have poor outcomes.
Major finding: Five-year progression-free survival approached 40% and 5-year overall survival was over 50%.
Study details: Retrospective analysis including 508 consecutive T-cell lymphoma patients receiving allogeneic transplants at 12 academic centers between 2000 and 2019.
Disclosures: Dr. Mehta-Shah reported research funding from Bristol Myers-Squibb, Celgene, Verastem, Corvus, Innate Pharmaceuticals, and Genentech/Roche. She reported consultancy with Kyowa Hakko Kirin, C4 Therapeutics, and Karyopharm Therapeutics.
Mehta-Shah N et al. ASH 2020, Abstract 41.